Entera Bio Ltd. Non-current Revenue (Deferred)

Non-current Revenue (Deferred) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-current Revenue (Deferred) growth rates and interactive chart.


Highlights and Quick Summary

  • Non-current Revenue (Deferred) for the quarter ending September 29, 2018 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Non-current Revenue (Deferred) decreased by NaN%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-current Revenue (Deferred) of Entera Bio Ltd.

Most recent Non-current Revenue (Deferred)of ENTX including historical data for past 10 years.

Interactive Chart of Non-current Revenue (Deferred) of Entera Bio Ltd.

Entera Bio Ltd. Non-current Revenue (Deferred) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2018 $0.0 $0.0 $0.0
2017 $0.0

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.